Journal
ESMO Open
Publication Date
7-1-2024
Volume
9
Issue
7
First Page
103625
Document Type
Open Access Publication
DOI
10.1016/j.esmoop.2024.103625
Rights and Permissions
Saleh M, Barve M, Subbiah V, Papadopoulos KP, Morgensztern D, Mettu NB, Roychowdhury S, Spanggaard I, Veronese ML, Tian C, Silverman IM, Gutierrez M. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies. ESMO Open. 2024 Jul;9(7):103625. doi: 10.1016/j.esmoop.2024.103625. © 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Saleh, M; Barve, M; Subbiah, V; Papadopoulos, K P; Morgensztern, D; Mettu, N B; Roychowdhury, S; Spanggaard, I; Veronese, M L; Tian, C; Silverman, I M; and Gutierrez, M, "Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies." ESMO Open. 9, 7. 103625 (2024).
https://digitalcommons.wustl.edu/oa_4/5187
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
